Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Physicians 59

pharmaphorum

OCTOBER 10, 2022

The results of the STELLAR trial showed that the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein achieved a significant increase in exercise capacity measured using the six-minute walking test in PAH patients when added to stable background therapy, hitting its primary objectives.

Sales 52

Sales FDA Pharma Competition 52

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Tivdak, a tissue-factor targeting ADC that was developed in collaboration with Genmab, was approved in 2021.

Engineering 59

Engineering Sales Patients Marketing 59

Pharmaceutical Technology

JANUARY 19, 2023

While allogeneic hematopoietic stem cell transplants (HSCT) provide long-term benefit to a subset of AML patients, other cell therapy modalities such as natural killer (NK) cells or chimeric antigen receptor (CAR)-T cells have failed to show conclusive benefit in late-stage clinical trials.

Marketing 52

Marketing FDA Sales Management 52

Medico Reach

MARCH 24, 2023

Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. To address the shortcomings of existing treatments, routine utilization of patient data becomes crucial. billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. To address the shortcomings of existing treatments, routine utilization of patient data becomes crucial. billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Pharmaceutical Technology

MARCH 22, 2023

The device received Breakthrough Device Designation from the US Food and Drug Administration (FDA) in December 2020 as no standard of care for the condition existed. There are at least 22 mHealth apps in product pipelines designed for patients with substance use disorders that fill this latter category and will require regulatory approval.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Medical 52

pharmaphorum

AUGUST 8, 2022

billion in 2028 – a leap forward from the $195 million it made last year and $127 million in the first half of 2022. $PFE $GBT [link] pic.twitter.com/52AMCbvFHF. — Brad Loncar (@bradloncar) August 8, 2022. Oxbryta is the main asset in the deal, with Evaluate predicting sales could reach $1.5

Marketing 102

Marketing Sales Pharma FDA 102

Pharmaceutical Technology

OCTOBER 28, 2022

In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. Merck, known outside of the US and Canada as MSD, is developing its portfolio of pneumococcal vaccines , and has secured an FDA approval for the paediatric use of its 15-serotype vaccine Vaxneuvance in June.

Training 64

Training Marketing Competition FDA 64

Contrarian Sales Techniques

FEBRUARY 10, 2023

They are designed to be safe and comfortable for patients, and typically have minimal side effects. According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

Pharmaceutical Technology

MARCH 30, 2023

On the same day, researchers presented new interim data from the Phase III RUBY trial of GSK’s PD-1 antibody Jemperli (dostarlimab) in patients with primary advanced or recurrent endometrial cancer. billion in 2028. As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Given the lower price of biosimilars, the patient share will be even higher than the market share, meaning that over 80% of US patients will have switched to biosimilar rituximab by 2029.

Sales 59

Sales Competition Marketing Patients 59

European Pharmaceutical Review

FEBRUARY 14, 2023

Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.” In August 2021, mRNA-1345 gained Fast Track designation from the US Food and Drug Administration (FDA) in adults over 60 years old.

Food and Drug Administration 90

Food and Drug Administration Medicine Safety Consulting 90

pharmaphorum

SEPTEMBER 13, 2022

Over the past two centuries, researchers have identified more than 100 different types of blood cancer, while most patients may be familiar with the big three (leukaemia, lymphoma, and melanoma). In 39-year-old patient Sarah Newbury, Solly observed the appearance of fatigue and bone pain resulting from multiple fractures.

Food and Drug Administration 87

Food and Drug Administration Patients Engineering Physicians 87

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

pharmaphorum

OCTOBER 18, 2022

per share – values Akouos at $487 million and includes another $3 per share in a contingent value right (CVR) ties to the enrolment of patients into the gene therapy company’s clinical trials. per month if conditions are not met, until the end of 2028 when they will all expire. The buyout – for $12.50

Medicine 52

Medicine FDA Patients Pharma 52

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Pharmaceutical Technology

AUGUST 24, 2022

CAGR between 2020 and 2028. Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. FCM provides the data to help researchers identify potential biomarkers to better understand why certain patients develop resistance to a therapy. The importance of validation.

Transportation 52

Transportation Patients Safety Marketing 52

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Food and Drug Administration 52

Food and Drug Administration FDA Prospecting Food 52

World of DTC Marketing

APRIL 7, 2022

Obesity costs our health care system $147 billion per year, yet there is a movement underway to tell HCPs not to weigh patients during routine visits. By 2028, these costs are expected to climb to $6.2 Food and Drug Administration (FDA). adults aged 20 and older are either overweight or obese. A study reported that U.S.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215